WO2001044186A1 - Derives de guanidine substitues - Google Patents
Derives de guanidine substitues Download PDFInfo
- Publication number
- WO2001044186A1 WO2001044186A1 PCT/JP2000/008669 JP0008669W WO0144186A1 WO 2001044186 A1 WO2001044186 A1 WO 2001044186A1 JP 0008669 W JP0008669 W JP 0008669W WO 0144186 A1 WO0144186 A1 WO 0144186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- unsubstituted
- methyl
- amino
- Prior art date
Links
- 150000002357 guanidines Chemical class 0.000 title description 5
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 140
- 150000003839 salts Chemical class 0.000 claims abstract description 70
- 229940002612 prodrug Drugs 0.000 claims abstract description 60
- 239000000651 prodrug Substances 0.000 claims abstract description 60
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 239000011734 sodium Substances 0.000 claims abstract description 21
- 125000003367 polycyclic group Chemical group 0.000 claims abstract description 20
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 15
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 13
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 12
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 135
- -1 R 42 Chemical compound 0.000 claims description 107
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 106
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 102
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 62
- 239000002253 acid Substances 0.000 claims description 55
- 125000000623 heterocyclic group Chemical group 0.000 claims description 54
- 229910052757 nitrogen Inorganic materials 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 125000004432 carbon atom Chemical group C* 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 36
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 35
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 19
- 125000001624 naphthyl group Chemical group 0.000 claims description 19
- 208000028867 ischemia Diseases 0.000 claims description 18
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 15
- 125000003277 amino group Chemical group 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 14
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims description 14
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 210000000056 organ Anatomy 0.000 claims description 13
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 12
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 230000004663 cell proliferation Effects 0.000 claims description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- 206010020772 Hypertension Diseases 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 10
- 150000002430 hydrocarbons Chemical group 0.000 claims description 10
- 206010002383 Angina Pectoris Diseases 0.000 claims description 9
- 206010019280 Heart failures Diseases 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 206010003119 arrhythmia Diseases 0.000 claims description 9
- 230000006793 arrhythmia Effects 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 210000002889 endothelial cell Anatomy 0.000 claims description 9
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 8
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 8
- 208000006029 Cardiomegaly Diseases 0.000 claims description 8
- 230000010410 reperfusion Effects 0.000 claims description 8
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 claims description 7
- 230000005779 cell damage Effects 0.000 claims description 7
- 208000037887 cell injury Diseases 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 6
- PVTXJGJDOHYFOX-UHFFFAOYSA-N 2h-1,4-benzoxazine Chemical compound C1=CC=C2N=CCOC2=C1 PVTXJGJDOHYFOX-UHFFFAOYSA-N 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000012038 nucleophile Substances 0.000 claims description 5
- DTRRHWQMEXXDFE-UHFFFAOYSA-N 8,9-dihydro-7h-benzo[7]annulene Chemical group C1CCC=CC2=CC=CC=C21 DTRRHWQMEXXDFE-UHFFFAOYSA-N 0.000 claims description 4
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical group C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 claims description 3
- BCVAGKRCMVWXOQ-UHFFFAOYSA-N 3-azatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),9,11-hexaene Chemical compound C1=CC=CC2=CNC3=CC=CC1=C32 BCVAGKRCMVWXOQ-UHFFFAOYSA-N 0.000 claims description 3
- GESDFCMCXNVUOI-UHFFFAOYSA-N 1,3,4,5-tetrahydrobenzo[cd]indole Chemical group C1=CC(CCC2)=C3C2=CNC3=C1 GESDFCMCXNVUOI-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical group OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 2
- 150000002475 indoles Chemical class 0.000 claims description 2
- PXPHCHJRHCHFGZ-UHFFFAOYSA-N 1,4-benzodiazocine Chemical compound N1=CC=NC=CC2=CC=CC=C21 PXPHCHJRHCHFGZ-UHFFFAOYSA-N 0.000 claims 2
- HXXJUMQRVNQWSF-UHFFFAOYSA-N 2,3-dihydro-1-benzoxepine Chemical compound O1CCC=CC2=CC=CC=C21 HXXJUMQRVNQWSF-UHFFFAOYSA-N 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 120
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 99
- 239000000203 mixture Substances 0.000 description 79
- 239000000243 solution Substances 0.000 description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 73
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 70
- 238000006243 chemical reaction Methods 0.000 description 69
- 238000003786 synthesis reaction Methods 0.000 description 65
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 64
- 230000002829 reductive effect Effects 0.000 description 61
- 239000002904 solvent Substances 0.000 description 59
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- 230000015572 biosynthetic process Effects 0.000 description 55
- 238000002844 melting Methods 0.000 description 51
- 230000008018 melting Effects 0.000 description 51
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 49
- 239000007787 solid Substances 0.000 description 49
- 238000000354 decomposition reaction Methods 0.000 description 48
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 41
- 238000001914 filtration Methods 0.000 description 34
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 25
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 24
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 23
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 22
- 239000010410 layer Substances 0.000 description 22
- 239000013078 crystal Substances 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 125000004430 oxygen atom Chemical group O* 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 18
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 17
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 125000004434 sulfur atom Chemical group 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 14
- 125000006239 protecting group Chemical group 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 13
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 13
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 12
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 12
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 12
- 229960004198 guanidine Drugs 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 229960000789 guanidine hydrochloride Drugs 0.000 description 11
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 125000001841 imino group Chemical group [H]N=* 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 125000000547 substituted alkyl group Chemical group 0.000 description 9
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 229940098779 methanesulfonic acid Drugs 0.000 description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 8
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 5
- 206010020880 Hypertrophy Diseases 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000005605 benzo group Chemical group 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- 125000005997 bromomethyl group Chemical group 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- GATNOFPXSDHULC-UHFFFAOYSA-N ethylphosphonic acid Chemical compound CCP(O)(O)=O GATNOFPXSDHULC-UHFFFAOYSA-N 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 4
- GCUOLJOTJRUDIZ-UHFFFAOYSA-N 2-(2-bromoethoxy)oxane Chemical compound BrCCOC1CCCCO1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 description 3
- ONJRTQUWKRDCTA-UHFFFAOYSA-N 2h-thiochromene Chemical compound C1=CC=C2C=CCSC2=C1 ONJRTQUWKRDCTA-UHFFFAOYSA-N 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 208000012998 acute renal failure Diseases 0.000 description 3
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 3
- 125000005138 alkoxysulfonyl group Chemical group 0.000 description 3
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007887 coronary angioplasty Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 206010061989 glomerulosclerosis Diseases 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 150000002463 imidates Chemical class 0.000 description 3
- 210000003584 mesangial cell Anatomy 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000008816 organ damage Effects 0.000 description 3
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 3
- 125000006684 polyhaloalkyl group Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 201000002793 renal fibrosis Diseases 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- FSSPGSAQUIYDCN-UHFFFAOYSA-N 1,3-Propane sultone Chemical compound O=S1(=O)CCCO1 FSSPGSAQUIYDCN-UHFFFAOYSA-N 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- LWZYUACNWRVDDJ-UHFFFAOYSA-N 1-benzoxepine Chemical compound O1C=CC=CC2=CC=CC=C12 LWZYUACNWRVDDJ-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-M 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)[O-])=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-M 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- WPWNEKFMGCWNPR-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromene Chemical compound C1=CC=C2CCCSC2=C1 WPWNEKFMGCWNPR-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- UTCMYCAFVUUNBK-UHFFFAOYSA-N benzo[cd]indole Chemical compound C1=CC(C=N2)=C3C2=CC=CC3=C1 UTCMYCAFVUUNBK-UHFFFAOYSA-N 0.000 description 2
- FBOSKQVOIHEWAX-UHFFFAOYSA-N benzothiazine Chemical compound C1=CC=C2N=CCSC2=C1 FBOSKQVOIHEWAX-UHFFFAOYSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004966 cyanoalkyl group Chemical group 0.000 description 2
- OIOCAANXMDJBLU-UHFFFAOYSA-N cyclohepta[b]pyridine Chemical compound C1=C=CC=C2C=CC=NC2=C1 OIOCAANXMDJBLU-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- BNKDGTGYTVFGBY-UHFFFAOYSA-N diethoxyphosphorylmethyl trifluoromethanesulfonate Chemical compound CCOP(=O)(OCC)COS(=O)(=O)C(F)(F)F BNKDGTGYTVFGBY-UHFFFAOYSA-N 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000004210 ether based solvent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 150000002905 orthoesters Chemical class 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 2
- 201000004240 prostatic hypertrophy Diseases 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 125000000464 thioxo group Chemical group S=* 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- DCFPGPVOAHTHCK-UHFFFAOYSA-N (2,3,4-trifluorophenyl)phosphane Chemical compound FC1=CC=C(P)C(F)=C1F DCFPGPVOAHTHCK-UHFFFAOYSA-N 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- IBJUOHSSKYWIIN-UHFFFAOYSA-N 1,4-benzoxathiine Chemical compound C1=CC=C2OC=CSC2=C1 IBJUOHSSKYWIIN-UHFFFAOYSA-N 0.000 description 1
- YQYZZTOIMUEGDJ-UHFFFAOYSA-N 1,4-dimethylindole Chemical compound CC1=CC=CC2=C1C=CN2C YQYZZTOIMUEGDJ-UHFFFAOYSA-N 0.000 description 1
- HGBGABMSTHQFNJ-UHFFFAOYSA-N 1,4-dioxane;sulfur trioxide Chemical compound O=S(=O)=O.C1COCCO1 HGBGABMSTHQFNJ-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 1
- QBDOBFNOPHZPCZ-UHFFFAOYSA-N 1-benzazocine Chemical compound N1=CC=CC=CC2=CC=CC=C21 QBDOBFNOPHZPCZ-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical compound C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 description 1
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- WSSWXGZEJNNFSN-UHFFFAOYSA-N 2,3-dihydro-1h-1-benzazepine Chemical compound N1CCC=CC2=CC=CC=C21 WSSWXGZEJNNFSN-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- YEKNLPSFGLBTCC-UHFFFAOYSA-N 3-[2-(diaminomethylidenecarbamoyl)-1,4-dimethylindol-7-yl]oxypropane-1-sulfonic acid Chemical compound CC1=CC=C(OCCCS(O)(=O)=O)C2=C1C=C(C(=O)NC(N)=N)N2C YEKNLPSFGLBTCC-UHFFFAOYSA-N 0.000 description 1
- WEOWIUDYMNVGLW-UHFFFAOYSA-N 3-[4-chloro-2-(diaminomethylidenecarbamoyl)indol-1-yl]propane-1-sulfonic acid Chemical compound C1=CC=C2N(CCCS(O)(=O)=O)C(C(=O)NC(=N)N)=CC2=C1Cl WEOWIUDYMNVGLW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FWURCAUKVVMKBJ-UHFFFAOYSA-N 3-azatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraene Chemical group C1CCCC2=CC=CC3=C2C1=CN3 FWURCAUKVVMKBJ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- LMIQERWZRIFWNZ-UHFFFAOYSA-N 5-hydroxyindole Chemical compound OC1=CC=C2NC=CC2=C1 LMIQERWZRIFWNZ-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- JWQNMZVYTPNHKI-UHFFFAOYSA-N Br.P(O)(O)=O Chemical compound Br.P(O)(O)=O JWQNMZVYTPNHKI-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- SBTYJUZFGGEWNU-SMYMAXHUSA-N N/1=C\C=NC=CC=C1 Chemical compound N/1=C\C=NC=CC=C1 SBTYJUZFGGEWNU-SMYMAXHUSA-N 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 241000506319 Trifur Species 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical group CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical group OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-M ethanimidate Chemical compound CC([O-])=N DLFVBJFMPXGRIB-UHFFFAOYSA-M 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- FYTWTGCZDHWMNL-UHFFFAOYSA-N ethyl 1-methyl-4-(trifluoromethyl)-6-(trifluoromethylsulfonyloxy)indole-2-carboxylate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)C=C2N(C)C(C(=O)OCC)=CC2=C1C(F)(F)F FYTWTGCZDHWMNL-UHFFFAOYSA-N 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- QVQUFBBIUUSKJG-UHFFFAOYSA-N ethyl 5-hydroxy-1,4-dimethylindole-2-carboxylate Chemical compound OC1=CC=C2N(C)C(C(=O)OCC)=CC2=C1C QVQUFBBIUUSKJG-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- GTTBQSNGUYHPNK-UHFFFAOYSA-N hydroxymethylphosphonic acid Chemical compound OCP(O)(O)=O GTTBQSNGUYHPNK-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- UTWGRMYWDUMKNY-UHFFFAOYSA-N indole-1-carboxylic acid Chemical compound C1=CC=C2N(C(=O)O)C=CC2=C1 UTWGRMYWDUMKNY-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical compound CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- DSWNRHCOGVRDOE-UHFFFAOYSA-N n,n-dimethylmethanimidamide Chemical compound CN(C)C=N DSWNRHCOGVRDOE-UHFFFAOYSA-N 0.000 description 1
- KCXYZMFPZHYUFO-UHFFFAOYSA-N n-methyl-n-phosphanylmethanamine Chemical compound CN(C)P KCXYZMFPZHYUFO-UHFFFAOYSA-N 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- FWFGVMYFCODZRD-UHFFFAOYSA-N oxidanium;hydrogen sulfate Chemical compound O.OS(O)(=O)=O FWFGVMYFCODZRD-UHFFFAOYSA-N 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- CNDQSXOVEQXJOE-UHFFFAOYSA-N oxyphenbutazone hydrate Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XDJOIMJURHQYDW-UHFFFAOYSA-N phenalene Chemical compound C1=CC(CC=C2)=C3C2=CC=CC3=C1 XDJOIMJURHQYDW-UHFFFAOYSA-N 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Definitions
- the present invention relates to a novel substituted guanidine derivative or a prodrug thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical use thereof, and a production method thereof.
- the compound of the present invention has a sodium proton (Na + ZH +) exchange transport system inhibitory action, and is a disease caused by an enhanced sodium proton (Na + ZH + ) exchange transport system, such as hypertension.
- Arrhythmia angina, cardiac hypertrophy, heart failure, diabetes, organ damage due to ischemia or ischemia reperfusion (eg, myocardial ischemia / reperfusion injury, acute renal failure, surgical treatment (eg, organ transplantation and ⁇ ⁇ CA (Percutaneous ransluminal Coronary Angioplasty)) Diseases caused by cell overgrowth (eg, fibroblast proliferation, smooth muscle cell proliferation, mesangial cell proliferation, etc.) (eg, atherosclerosis, lung Fibrosis, hepatic fibrosis, renal fibrosis, glomerulosclerosis, organ hypertrophy, prostatic hypertrophy, diabetic complications, restenosis after PTCA, etc.), useful for the treatment and prevention of diseases due to endothelial cell disorders That.
- ischemia or ischemia reperfusion eg, myocardial ischemia / reperfusion injury, acute renal failure, surgical treatment (eg, organ transplantation and ⁇ ⁇ CA (Percutaneous ransluminal Corona
- Examples of the substituted guanidine derivatives having an inhibitory effect on sodium / proton (Na + ZH +) exchange transport system include, for example, JP-A-7-10839, JP-A-8-208602, and JP-A-10-237073. And the compounds described in JP-A-9-291076 and International Publication (W0) 9961414.
- the present inventors have conducted intensive studies in order to achieve the above object, and as a result, have found that the compound represented by the general formula (1) or a prodrug thereof or a pharmaceutically acceptable salt thereof (hereinafter referred to as the compound of the present invention as necessary) (Sometimes abbreviated) has an excellent inhibitory effect on the Na + ZH + exchange transport system, and significantly improves the side effects on the nervous system, especially on the central nervous system. That is, the present invention relates to the following. [1]
- R represents a substituted or unsubstituted benzene ring, a substituted or unsubstituted fused polycyclic hydrocarbon ring, a substituted or unsubstituted monocyclic heterocyclic ring, or a substituted or unsubstituted polycyclic heterocyclic ring.
- G represents a single bond or a group represented by the formula: O— or —N (R 11 ) —.
- Y is the formula: A S0 3 DOO I, one P0 3 H 2, one C_ ⁇ 2 H or
- RR 11 and R are each independently a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, An unsubstituted cycloalkenyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted naphthyl group, or a substituted or unsubstituted heterocyclic group, or a substituted or unsubstituted acyl group, or a formula: —C (-0) N (R 5 ) R 6 ,
- 5 represents a group or a substituted or unsubstituted heterocyclic group.
- n an integer of 0, 1 or 2.
- a S 0 is a group represented by 3 H [1], [2] or [3] acceptable salt compound or a prodrug or pharmaceutical of description.
- a P 0 3 salt compound is a group represented with H 2 [1] or [2], wherein also properly is acceptable as a prodrug or pharmaceutical.
- R is 1H-indene, 1,2-dihydronaphthalene, 6,7-dihydro 5H monobenzocycloheptene, 2,3-dihydro-1H-benz [b] azepine or 2,3 —Dihidrobene's [b] oxepin, which is substituted or unsubstituted, the compound according to [2], [3], [4], [5], [6] or [7] or a compound thereof; Prodrugs or their pharmaceutically acceptable salts.
- R is substituted or unsubstituted 6,7-dihydro-5H-benzocycloheptene; the compound according to [2], [3], [4], [5], [6] or [7]; Is a prodrug thereof or a pharmaceutically acceptable salt thereof.
- R is 1,3,4,5-tetrahydrobenz [cd] indole or 3,4,5,6-tetrahydro-1H-cyclohepta [cd] indole, which may be substituted or unsubstituted.
- R is 5,6-dihydro-4H-pyro mouth [3,2,1-ij] quinoline, 2,3-dihydro-pyro mouth [1,2,3-de] [1,4] benzoxazine, 2, 3 Dihydro-1H-pyro [1,2,3-de] quinoxaline, 4,5-dihydroxypyro [3,2,1-hi] indole, 4,5,6,7-tetrahydropyro [ 3,2,1-jk] [1] benzazepine, 5,6,7,8-tetrahydro 4H-pyro [3,2,1 ⁇ k1] [1] benzazosin, 4,5,7,8 —Tetrahydropyro [3,2,1-k 1] benz [e] [1,4] oxazosin or 4,5,7,8-tetrahydropyro [3,2,1.1 kl ] Ben Zo [e] [1, 4] diazocine, which is substituted or unsubstituted, the compound
- R is 5,6,7,8-tetrahydro-4H-pyro [3,2,1-k1] [1] benzozocine, 4,5,7,8-tetrahydropyro [3,2, 1-1] benz [6] [1,4] oxazosin or 4,5,7,8-tetrahydropyrro [3,2,1-kl] benzo [e] [1,4] diazosin, These are substituted or unsubstituted compounds of [2], [3], [4], [5], [6] or [7] or a prodrug thereof or a pharmaceutically acceptable drug thereof. Salt.
- R 40 , R 41 , R 42 , R 43 and R 44 each independently represent a substituted or unsubstituted alkyl group.
- [1 7] A pharmaceutical composition comprising the compound according to any one of [1] to [16], a prodrug thereof, or a pharmaceutically acceptable salt thereof.
- a pharmaceutical composition for inhibiting the sodium Z-proton exchange-transport system comprising the compound according to any one of [1] to [16] or a prodrug thereof or a pharmaceutically acceptable salt thereof.
- compositions for the treatment or prevention of hypertension, arrhythmia, angina, heart failure, cardiac hypertrophy, diabetes, organ inhibition due to ischemia or ischemia reperfusion, diseases caused by excessive cell proliferation, or diseases caused by endothelial cell damage
- a prodrug thereof or a pharmaceutically acceptable salt thereof for producing a composition.
- Sodium z-proton exchange comprising administering to a subject in need of an effective amount of the compound according to any of [1] to [16] or a prodrug thereof or a pharmaceutically acceptable salt thereof. How to inhibit the transport system. ⁇ twenty four ⁇
- Hypertension, arrhythmia, angina including administering to a subject in need of an effective amount of the compound according to any of [1] to [16] or a prodrug thereof or a pharmaceutically acceptable salt thereof.
- Equation (1) consisting of:
- G has the formula: A O- or _N (R 1 1) - represents a group represented by (R 1 1 represents the same meaning as in [1])] A compound represented by the trioxide Iou (SO 3) Or reacting with the complex thereof, formula (12):
- the compound of the present invention has a property that it is hardly distributed centrally, for example, when administered systemically, for example, by oral administration or intravenous administration, and thus, for example, hypertension, arrhythmia, angina pectoris, heart failure, Organ hypertrophy, diabetes, organ damage due to ischemia or ischemia reperfusion (eg, myocardial ischemia reperfusion injury, acute renal failure, surgical treatment (eg, damage caused by organ transplantation or PTC A (Percutaneous Transluminal Coronary Angioplasty)) Diseases caused by cell overproliferation (eg, fibroblast proliferation, smooth muscle cell proliferation, mesangial cell proliferation, etc.) (eg, atherosclerosis, pulmonary fibrosis, liver fibrosis, renal fibro
- the condensed polycyclic hydrocarbon ring, monocyclic heterocyclic ring and polycyclic heterocyclic ring in R are each described below in which two hydrogen atoms of each ring are replaced by a bond. To taste. In the above [6] to [12], specific ring names are described as R, but these also mean that two hydrogen atoms in each ring are replaced by a bond.
- the heterocyclic group includes a monocyclic heterocyclic group and a polycyclic heterocyclic group, each of which has one hydrogen atom in each of the monocyclic heterocyclic and polycyclic heterocyclic rings described below. It means something that has changed to a bond.
- the condensed polycyclic hydrocarbon ring group means one in which one hydrogen atom of the condensed polycyclic hydrocarbon ring described below has been changed to a bond.
- the saturated heterocyclic group means one in which one hydrogen atom of the saturated heterocyclic ring described below is changed to a bond.
- saturated heterocycle examples include the following 3- to 8-membered saturated complex monocyclic ring containing 1 to 4 nitrogen atoms, and 3 to 8 containing 1 to 3 nitrogen atoms and 1 to 2 oxygen atoms. And a 3- to 8-membered saturated heterocyclic monocyclic ring containing 1 to 3 nitrogen atoms and 1 to 2 sulfur atoms.
- Examples of the condensed polycyclic hydrocarbon ring include indene, naphthalene, azulene, phenololene, phenalene, phenanthrene, anthracene, acephenanthrylene, 1,2-dihydronaphthalene, and 6,7-dihydro-5-benzo.
- Examples include condensed polycyclic hydrocarbon ring groups having 16 or less carbon atoms, such as cycloheptene and benzocyclootaten, and preferably include indene, naphthalene, and 6,7-dihydro-5H-benzocycloheptene.
- monocyclic heterocyclic ring a 3- to 8-membered unsaturated heterocyclic monocyclic ring containing 1 to 4 nitrogen atoms, a 3- to 8-membered saturated heterocyclic monocyclic ring containing 1 to 4 nitrogen atoms, 1 3 to 8 membered unsaturated monocyclic ring containing 2 oxygen atoms,].
- a 3- to 8-membered unsaturated heteromonocycle containing 4 to 4 nitrogen atoms for example, pyrrole, pyrroline, pyridine, dihydropyridine, imidazole, pyrazole, imidazoline, virazine, pyrimidine, pyridazine, pyrazole , Triazole, tetrazole and the like, preferably pyrrole, pyridine, imidazole, pyrazine, pyrimidine and the like.
- Examples of the 3- to 8-membered unsaturated heterocyclic monocyclic ring containing one oxygen atom include furan and pyran.
- Examples of the 3- to 8-membered unsaturated heterocyclic monocyclic ring containing! To 3 nitrogen atoms and 1 to 2 oxygen atoms include oxazole, oxazidazole, isoxazole and the like.
- Examples of the 3- to 8-membered saturated heteromonocyclic ring containing up to 3 nitrogen atoms and 1 to 2 oxygen atoms include morpholine and oxazolidin.
- Examples of the 3- to 8-membered unsaturated heterocyclic ring containing 1 to 3 nitrogen atoms and 1 to 2 sulfur atoms include thiazole, isothiazole, thiadiazole and the like.
- Examples of the 3- to 8-membered saturated heterocyclic monocyclic ring containing up to 3 nitrogen atoms and 1 to 2 sulfur atoms include thiazolidine.
- the polycyclic heterocyclic ring examples include unsaturated condensed heterocyclic rings containing 1 to 4 nitrogen atoms, unsaturated condensed heterocyclic rings containing 1 to 3 nitrogen atoms and 1 to 2 oxygen atoms, 1 Unsaturated condensed heterocyclic ring containing ⁇ 3 nitrogen atoms and 1-2 sulfur atoms, unsaturated condensed heterocyclic ring containing 1-2 oxygen atoms, 1 oxygen atom and 1-2 Examples include an unsaturated fused heterocyclic ring containing a sulfur atom and an unsaturated fused heterocyclic ring containing 1 to 2 sulfur atoms.
- unsaturated condensed heterocycles containing 1 to 4 nitrogen atoms include, for example, indole, isoindole, indoline, quinoline, isoquinoline, quinolidine, indazole, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, force rubazole, purine , Pteridine, phenazine, carbolinin, phenanthridine, acridine, indoline, isoindoline, 1,2-dihydroisoquinoline, benzimidazole, imidazopyridine, benzotriazole, tetrahydroidmidazopyridine, benz [b] azepine, benzine [b] cd Indole, cyclohepta [cd] indonele, pyro-mouth [3,2,1-ij] quinoline, cyclohexa [b] pyridine, cyclohepta
- an unsaturated condensed heterocycle containing 1 to 3 nitrogen atoms and 1 to 2 oxygen atoms for example, benzoxazole, benzoxadiazole, phenoxazine, pyrrole [1,2,3-de ] [1,4] benzoxazine, pyro-mouth [2,1-c] [1,4] benzo-oxazine, pyro-mouth [3,2,1-kl] benz [e] [4,1] oxazosin, etc.
- Examples of the unsaturated condensed heterocyclic ring containing 1 to 3 nitrogen atoms and 1 to 2 sulfur atoms include, for example, benzothiazole, benzothiadiazole, 1,4-benzothiazine, phenothiazine and the like, and preferably benzothiazole, 1 , 4 Benzothiazine.
- Examples of the unsaturated condensed heterocyclic ring containing one or two oxygen atoms include benzofuran, dihydrobenzofuran, chromene, isobenzofuran, xanthene, isochromane, chroman, benz [b] oxepin and the like. Examples include benzofuran and benz [b] oxepin.
- Examples of the unsaturated condensed heterocyclic ring containing one oxygen atom and one or two sulfur atoms include 1,4-benzoxathiin and phenoxatiin.
- Examples of the unsaturated condensed heterocyclic ring containing one or two sulfur atoms include benzothiophene, benzothiin, benzothiopyran, thiochroman, and thianthrene, and preferably benzothiophene, benzothiopyran, and thiochroman.
- the substituents on the benzene ring, the condensed polycyclic hydrocarbon ring, the monocyclic heterocyclic ring and the polycyclic heterocyclic ring may be one or more, and may be the same or different.
- a hydrogen atom a substituted or unsubstituted alkyl Group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted cycloalkyl group, Or unsubstituted cycloalkenyl group, substituted or unsubstituted fuynyl group, substituted or unsubstituted naphthyl group, substituted or unsubstituted heterocyclic group, substituted or unsubstituted acyl group, carboxy group, halogen atom , A nitro group, or a formula: —CN, one
- n an integer of 0 1 or 2;
- R] 2 and R 2 1 are each independently hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, phenyl group, a naphthyl group, a heterocyclic group, or Ashiru group, the ring is 3-8 membered Represents a saturated heterocyclic group consisting of one nitrogen atom and a carbon atom),
- R 1 3 and R 1 3 a are, independently of one another, human Dorokishi group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted Fuyuniru group, a substituted or unsubstituted naphthyl group or a substituted or unsubstituted, Represents a heterocyclic group.
- R 15 , R 16 , R 17 and R 18 each independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group A substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted naphthyl group, a substituted or unsubstituted heterocyclic group, or a substituted or unsubstituted R 15 and R 16 , or R 17 and R 18 are bonded to each other to form another heteroatom in the ring together with the nitrogen atom to which they are bonded.
- R 14 , 13 ⁇ 414 £ 1 or 1 413 independently of one another is a hydrogen atom, an alkyl group, a cycloalkyl group, a cycloalkenyl group, a phenyl group, a naphthyl group, a heterocyclic group, or It represents the 3 H.
- the substituted alkyl group may have one or more substituents, which may be the same or different, and the substituted alkyl group may for example have 3 to 6 carbon atoms.
- Alkyl Group an amino-C1-C5 alkyl group in which a nitrogen atom may be substituted by one or two C1-C3 alkyl or C7-C11 aralkyl, a saturated 5- to 7-membered cyclic amino-1-C1-C3 alkyl group, etc. .
- One or more substituents for the saturated heterocyclic monocarbonyl group and the heteroaromatic acyl group may be the same or different and include, for example, an alkyl group, an alkenyl group, Examples thereof include an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a saturated heterocyclic group, a phenyl group, a naphthyl group, a heterocyclic group, an acyl group, a carboxy group, a halogen atom and a nitro group.
- Cycloalkyl group examples of the substituent of the cycloalkyl Anore Ke cycloalkenyl group and a cycloalkane carbonyl group, for example 1-4, the same or different alkyl group, a substituted aralkyl kill group, hydroxyl group or formula: is represented by a OR 3 4 Groups.
- the group represented by R 3 4, include the same groups as the groups represented by R 4.
- alkyl group examples include straight-chain or branched groups such as methyl, ethyl, propyl, 2-propyl, butyl, 2-butyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, hexyl, heptyl, and octyl.
- Alkyl groups having 8 or less carbon atoms examples include straight-chain or branched groups such as methyl, ethyl, propyl, 2-propyl, butyl, 2-butyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, hexyl, heptyl, and octyl.
- Alkyl groups having 8 or less carbon atoms examples include straight-chain or branched groups such as methyl, ethyl, propyl, 2-propyl, butyl, 2-butyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl
- cycloalkynole group examples include cyclopropyl, cyclobutyl, cyclopentynole, cyclohexyl, cycloheptyl, 2-methynolecyclopentynole, 3-methynolecyclopentyl, 2-methylcyclohexyl, 3-methylcyclohexyl, 4-Methylcyclohexynole, 2-hydroxycyclopentynole, 3-hydroxycyclopentynole, 2-hydroxycyclohexynole, 3-hydroxycyclohexynole, 4-hydroxycyclohexynole, 2- (hydroxymethynole) cyclo Pentinole, 3- (Hydroxymethinole) Cyclopentinole, 2- (Hydroxymethinole) Cyclohexinole, 3— (Hydroxymethinole) Cyclohexinole, 41- (Hydroxymethylen ⁇ ) Cyl
- the cycloalkane ring in the definition of A and E means that two hydrogen atoms of the cycloalkane ring are changed to a bond to form a divalent group, and specifically, a 3- to 8-membered ring
- Examples thereof include a cycloalkane ring, and more specifically, one in which one of the hydrogen atoms of the above cycloalkyl group is changed to a bond to form a divalent group.
- the cycloalkenyl group include 3- to 8-membered rings such as 1-cyclopentenyl, 2-cyclopenteninole, 3-cyclopenteninole, 1-cyclohexeninole, 2-cyclohexeninole, and 3-cyclohexenyl. Examples thereof include a cycloalkenyl group having one heavy bond.
- alkenyl group examples include alkenyl groups having 6 or less carbon atoms, such as vinyl, aryl, propenyl, 2-propenyl, butenyl, pentenyl, and hexenyl.
- alkynyl group examples include alkynyl groups having 6 or less carbon atoms, such as ethur, propargyl, butcher, and pentenyl.
- halogen atom examples include iodine, fluorine, chlorine and bromine atoms.
- acyl group examples include a formyl group, for example, an alkanoyl group having 2 to 6 carbon atoms such as acetyl and propanol, and a carbon atom such as cyclopropanecarbonyl, cyclobutane canolebonyl, cyclopentane canoleponinole, and cyclohexane canoleboninole.
- a formyl group for example, an alkanoyl group having 2 to 6 carbon atoms such as acetyl and propanol
- a carbon atom such as cyclopropanecarbonyl, cyclobutane canolebonyl, cyclopentane canoleponinole, and cyclohexane canoleboninole.
- a cycloalkanecarbonyl group having the number of 4 to 7 such as cyclopentenecarbonyl and cyclohexenecarboninole, and a C3 to C6 cycloanoleken canoleboninole group such as benzoyl, toluoyl, and naphthoyl having 6 carbon atoms;
- a saturated heterocyclic monocarbonyl group having a saturated heterocyclic ring for example, A heteroaromatic acyl group having a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected from nitrogen, oxygen, and sulfur, such as yl, tenoyl, nicotinoyl, and isonicotinoyl. .
- One or more substituents in the substituted alkyl group may be the same or different and may be substituted with a halogen atom, a hydroxyl group, an alkoxy group, a cycloalkyl group, a cyano group, a carboxy group, an acyl group, a substituted or unsubstituted group.
- R represents a hydrogen atom, an alkyl group, or a substituted alkyl group, and the ring represents a saturated heterocyclic group consisting of one 3- to 8-membered nitrogen atom and a carbon atom, wherein the substituent of the substituted alkyl group is And a halogen atom, a hydroxyl group, an alkoxy group, a cycloalkyl group, a cyano group, a carboxy group, an acyl group, a phenyl group, a naphthyl group, a heterocyclic group, an oxo group and a thioxo group. .
- R 3 3, R 3 5 and R 3 6, wherein each of the R l, include the same groups as R 1 5 and R 1 6.
- Examples of such a substituted alkyl group include an alkyl group having 1 to 5 carbon atoms substituted with a cycloalkyl having 3 to 6 carbon atoms, a polyhaloalkyl group having 1 to 5 carbon atoms, and a 1 to 6 carbon atoms.
- Amino one C1 ⁇ C5 ⁇ be alkyl groups include saturated 5 to 7 membered cyclic Amino one C1 ⁇ C 3 alkyl group.
- Typical substituted alkyl groups include polyhaloalkyl groups having 1 to 3 carbon atoms, such as trifluoromethyl, trifluoroethyl, and trichloromethyl, and carbon atoms such as hydroxymethyl, hydroxyethyl, and 1-hydroxyethyl. 1 to 6 hydroxyalkyl groups, aminomethyl, aminoethyl, 1-aminoethyl, etc.
- C1 to C5 aminoalkyl groups methoxyxethyl, ethoxyxyl, methoxypropyl and other C1 to C6 alkoxyalkyl groups, carboxyethyl, carboxypropyl and other C2 to C6 carboxyalkyl groups, C3-C7 alkoxycarbonylalkyl groups such as methoxycanoleponylmethyl, ethoxycanolevonylmethinole, methoxycanoleponinoleethyl, benzyl, pheninolethinole, phenylpropinole, phenylinolebutinole, 1- or 2-naphthynolemethyl and other phenyl or naphthyl-C1-C5 alkyl groups (substitution of C1-C3 alkyl groups, halogen atoms, nitro groups, amino groups, hydroxyl groups, C1-C3 alkoxy groups in the phenyl or naphth
- Examples of the substituent in the substituted alkenyl group, substituted alkynyl group, or substituted alkanoyl group include the same groups as the above-mentioned substituted alkyl group.
- the substituents of these groups may be substituted one or more times, the same or different.
- aralkyl group examples include an alkyl group substituted with a phenyl group or a condensed polycyclic hydrocarbon ring group.
- R 15 and R 16 , R 7 and R 8 , R 17 and R 18 , or Rp and Rq are bonded to each other to form together with the nitrogen atom to which they are bonded.
- the hetero atom of the saturated 5- to 7-membered cyclic amino group which may contain a hetero atom include an oxygen atom, a nitrogen atom and a sulfur atom, and specifically, for example, 1 to 3 nitrogen atoms 5 to 7-membered ring group or a 5- to 7-membered ring group containing one nitrogen atom and one oxygen atom, and more specifically, 1-pyrrolidinyl, 1-piperidino, 1-pi Radinyl, morpholino, and 11- (4-methyl) piperazinyl.
- a S (O) 2 R 3, a group represented by one S (O) 2 R 3 a , one S (O) 2 R 1 3 or _S (O) 2 R 1 " a, e.g.
- the alkylsulfonyl group having 8 or less carbon atoms such as a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, and an isopropylsulfonyl group, include a group represented by the formula: 1 S (O) n R 3 , Examples of the group include a corresponding alkylsulfinyl group or alkylthio group, or a sulfo group.
- alkenylene group and alkynylene group one or more, the same or different, for example, a halogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, a cycloalkenyl group, a saturated heterocyclic group, a carboxy group Group, alkoxycarbonyl group, phenyl group, naphthyl group, heterocyclic group, and formula
- R 45 and R 46 include the same groups as R 15 and R 16 described above.
- Examples of the lower alkylene group include an alkylene group having 10 or less carbon atoms, such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, and hexamethylene.
- the compound of the present invention can be synthesized, for example, by the following method.
- the product is a prodrug or a pharmaceutically acceptable salt thereof.
- the compound of the present invention can be synthesized by conversion into
- Leaving groups that can be displaced by a nucleophile include, for example, halogen atoms (eg, fluorine, chlorine, bromine), lower alkoxy groups (eg, methoxy, ethoxy, etc.), aralkyloxy groups (eg, benzyloxy group, etc.), Examples thereof include an aryloxy group (for example, a phenoxy group), and a group formed by a compound in which L is a hydroxyl group and a condensing agent.
- the method for producing the carboxylic acid represented by the formula (2) or a reactive derivative thereof in which L is one of these groups will be specifically described as follows.
- Examples of the reactive derivative of the carboxylic acid represented by the formula (2) include an acid halide, an acid anhydride (including a mixed acid anhydride) or an ester derivative.
- the acid halide may be an acid halide. Chloride or acid bromide, mixed acid anhydrides such as ethyloxycarboyl chloride, isobutyloxycarboyl or the like, and alkyloxycarboyl chloride such as 2-ethylethyl chloride; Mixed acid anhydrides with ⁇ -polyalkyl-substituted carboxylic acid chlorides such as n-butyryl and trimethylacetyl chloride, and ester derivatives such as ⁇ -nitrophenyl ester, ⁇ -hydroxys succinimide esterol, and pentaphnolerophenyl Estenoles such as estenole and general esters such as methyl ester and ethyl ester .
- Such a reactive derivative of a carboxylic acid can be easily
- the base include inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, and sodium hydrogen carbonate, and organic bases such as triethylamine and pyridine
- the solvent include aromatic hydrocarbons such as benzene, toluene, and xylene.
- Solvents such as ether solvents such as tetrahydrofuran and 1,4-dioxane, halogenated hydrocarbon solvents such as dichloromethane, chlorophonolem and 1,2-dichloroethane, and amides such as dimethylformamide and dimethylacetamide Solvents, basic solvents such as pyridine, and mixtures thereof.
- ether solvents such as tetrahydrofuran and 1,4-dioxane
- halogenated hydrocarbon solvents such as dichloromethane, chlorophonolem and 1,2-dichloroethane
- amides such as dimethylformamide and dimethylacetamide Solvents
- basic solvents such as pyridine
- an active ester for example, in the case of another ester in an ether solvent such as tetrahydrofuran, 1,2-dimethoxetane or dioxane, an ester solvent such as ethyl acetate, dimethylformamide or a mixed solvent thereof.
- the reaction is preferably performed in an alcoholic solvent such as methanol, ethanol, or isopropanol, an ethereal solvent such as tetrahydrofuran, 1,2-dimethyloxetane, or dioxane, dimethylformamide, or a mixed solvent thereof.
- an alcoholic solvent such as methanol, ethanol, or isopropanol
- an ethereal solvent such as tetrahydrofuran, 1,2-dimethyloxetane, or dioxane, dimethylformamide, or a mixed solvent thereof.
- heating at about 130 ° C for a short time is also possible.
- the compound wherein L is a hydroxyl group is preferably reacted with guanidine at room temperature or under heating in an inert solvent in the presence of a condensing agent to obtain a compound represented by the formula (1).
- the compounds represented can be obtained.
- the reactions are, for example, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPC), 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimid (WSC), benzotriazole-1 —Elutris (dimethylamino) phosphonium 'hexafluorophosphoride salt (B ⁇ P), dipheninolephosphoninoleazide (DP PA), N, N-canoleboninolegi midazonole (Angew. Chem. Int. Ed. Engl., Vol.
- aromatic hydrocarbon solvents such as benzene, toluene, and xylene
- ether solvents such as tetrahydrofuran and 1,4-dioxane
- halogenated hydrocarbons such as dichloromethane, chloroform, and 1,2-dichloroethane It is preferably carried out in a system solvent, an amide solvent such as dimethylformamide or dimethylacetamide, a basic solvent such as pyridine, or a mixed solvent thereof.
- G is the formula: O or N (R 1 1) - represents a group represented by (R 1 1 are as defined above)]
- the compound represented by is reacted with sulfur trioxide or a complex thereof to form a sulfo group (one SO 3 H group) at the position of G, and the formula (12):
- the reaction is carried out in a solvent that is inert to this reaction (eg, halogenated hydrocarbon solvents such as chloroform, methylene chloride, sulfuric acid, pyridine, and triethylamine).
- a solvent that is inert to this reaction eg, halogenated hydrocarbon solvents such as chloroform, methylene chloride, sulfuric acid, pyridine, and triethylamine.
- Sulfur trioxide (so 3 ) or a complex thereof for example, sulfur trioxide-pyridine complex, sulfur trioxide-dioxane complex, sulfur trioxide-trimethylamine complex, etc.
- the reaction is carried out at a temperature between ° C and room temperature.
- the compound represented by the formula (2) can be produced by a known force or by a combination of known methods. It can be manufactured by a conventional method.
- the compound is Y Gar S_ ⁇ 3 H
- equation (2) has the formula (4):
- (R 11 ) — represents a group represented by (R 11 represents the same meaning as described above).] ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ Organic Organic, Organic functional group preparations, second edition; Wasserman, HH; Academic Press: London, 1983; Vol. 1, pp. 619-639) or by reacting with sulfur trioxide or a complex thereof as in (B) above.
- reaction conditions with sulfur trioxide or a complex thereof, a reaction reagent, and the like include the same as those described in the above (B).
- the compound represented by is, for example, a compound described in the above-mentioned patent gazette or the like, or a compound (for example, New Experimental Chemistry Course Vol. 14, Vol. Reaction (V), by introducing a group of the above formula or a group in which the functional group is protected by the method described in 24, 22 to 24, 29), followed by deprotection at an appropriate stage. Can be.
- G is a group represented by the formula: — O— or — N (R 11 ) —
- Y is the formula:
- the compound represented by OH is represented by the formula (4)
- Examples of the compound represented by the formula (6) include, but are not limited to, D-glucuronic acid, L-iduronic acid-dalcuronic acid, D-mannuronic acid, D-galataturonic acid, and the like.
- reaction of the compound represented by the formula (6) with a reactive derivative may be carried out, for example, by protecting the hydroxyl group or the carboxy group of the above compound (for example, the protected form of the hydroxyl group may be acetyloxy or benzyloxy).
- the protected form of the carboxy group include benzyl esters.
- Reactive derivatives for example, imidate derivatives:
- imidate method for example, Helvetica Chimica Acta, 79, 1757-1784 (1996).
- a solvent inert to the reaction for example, a halogenated hydrocarbon solvent such as chloroform and methylene chloride, etc.
- a Lewis acid for example, boron trifluoride / getyl ether complex
- the reaction can be carried out usually at ⁇ 30 ° C. to the boiling point of the solvent, preferably at 0 ° C. to room temperature in the presence of.
- the deprotection of the carboxy group is preferably carried out at a stage prior to the next step, that is, the guanidination of the above (A).
- the compound represented by the formula (4) has a group active in a reaction such as a hydroxyl group or a amino group in the side chain, it is not necessary. Accordingly, these groups may be protected with an appropriate protecting group in advance, and after performing this reaction, the protecting group may be removed.
- R 11 represents a group represented by the formula (R 11 represents the same meaning as described above)
- reaction conditions for guanidine, the reaction reagent, and the like include the same as those described in (A) above.
- (C) Formula (1) in the Y has the formula: - P0 3 H compound is a group represented by 2, may be prepared by the following method if example embodiment.
- a compound represented by the formula: P (OR 41 ) (OR) is prepared by a method described in a literature (for example, the fourth edition of Experimental Chemistry Course, Vol. 24, Organic Synthesis VI, pp. 248 to 249).
- the reaction with a phosphite triester is usually carried out in the absence of a solvent at a reaction temperature of 100 ° C to 200 ° C for a reaction time of 1 to 5 hours.
- the reaction with a phosphite diester is usually carried out with tetrahydrofuran or the like.
- the reaction is carried out in an ether solvent or in dimethylformamide, for example, in the presence of a base such as potassium tert-butoxide at a reaction temperature of 20 ° C to 30 ° C and a reaction time of 1 to 5 hours.
- reaction conditions include those described in the above (A).
- the reaction can be performed, for example, by reacting in a halogen-based solvent such as dichloromethane or acetonitrile or dimethylformamide at a reaction temperature of 20 ° C to 100 ° C for 1 to 3 days (for example, described in Synthesis 485 (1993)). Note that by selectively removing only R 4 3, the formula (9)
- R 4 2, ⁇ , the R and ⁇ represent the same meaning as the above] can be manufacturing a compound represented by.
- a benzyl group when used as R 4 °, it can be produced by a usual reaction for removing a benzyl group (for example, the method described in Protective Groups in Organic Synthesis, JOHN WILLEY & SONS, 1991).
- a guanidinocarbonyl group or a compound represented by the formula: 1S ⁇ gH or It can be manufactured by introducing a group represented by HO ⁇ OH OH and synthesizing a basic skeleton.
- the compound can be synthesized from a compound in which L in the formula (4) is a hydroxyl group according to a general method generally used.
- L in the formula (4) is a hydroxyl group according to a general method generally used.
- the starting compound for each reaction has a group active in the reaction, such as a hydroxyl group, an amino group or a hydroxyl group, if necessary, these groups are previously protected with an appropriate protecting group.
- the desired compound can be obtained by protecting it and removing the protecting group after each reaction or after performing some reactions.
- a protecting group for protecting a hydroxyl group, an amino group, a carboxy group, etc. a normal protecting group used in the field of synthetic organic chemistry may be used, and such a protecting group may be introduced or removed according to a usual method.
- a protecting group for a hydroxyl group includes a methoxymethyl group and a tetrahydrobiranyl group
- a protecting group for an amino group includes a tert-butyloxycarbonyl group.
- Such a hydroxyl-protecting group can be removed, for example, by reacting with a solvent such as aqueous methanol, aqueous ethanol, or aqueous tetrahydrofuran in the presence of an acid such as a base, sulfuric acid, or acetic acid.
- the protecting group can be removed, for example, by reacting in the presence of an acid such as hydrochloric acid or trifluoroacetic acid in a solvent such as hydrated tetrahydrofuran, methylene chloride, chloroform, or hydrated methanol.
- an acid such as hydrochloric acid or trifluoroacetic acid
- a solvent such as hydrated tetrahydrofuran, methylene chloride, chloroform, or hydrated methanol.
- the form of protection includes, for example, tert-ter, orthoester, acid amide and the like.
- the removal of such a protecting group is carried out, for example, by reacting in the presence of hydrochloric acid in a solvent containing water, and in the case of the ortho ester, for example, aqueous methanol, water-containing tetrahydrofuran,
- the treatment is carried out by treating with an acid in a solvent such as 1,2-dimethoxetane containing water, followed by treatment with an alkali such as sodium hydroxide.
- an acid amide for example, an acid such as hydrochloric acid or sulfuric acid is used.
- the reaction can be carried out in the presence of a solvent such as water, hydrated methanol, or hydrated tetrahydrofuran.
- the compounds of the formula (1) also include those having an optically asymmetric center, so that they can be obtained as racemates or, if optically active starting materials are used, in optically active form. If necessary, the racemates obtained can be physically or chemically resolved into their optical antipodes by methods known per se.
- a diastereomer is formed from a racemate by a reaction using an optically active resolving agent. The diastereomers in different forms can be separated by methods known per se, for example by fractional crystallization.
- Examples of “prodrugs” include those that are easily hydrolyzed in vivo to regenerate the compound of the formula (1).
- the carboxylic acid group becomes an alkoxycarbonyl group.
- the compound include a compound, a compound having an alkylthiocarbonyl group, and a compound having an alkylaminocarbonyl group.
- acyloxymethyl A compound that has become an amino group or a compound that has become a hydroxylamine.
- a compound having a hydroxyl group a compound in which the hydroxyl group is substituted with the above-mentioned acyl group to form an acyloxy group, a compound which becomes a phosphoric ester, or a compound in which the hydroxyl group becomes an acyloxymethyloxy group is exemplified.
- a compound having a sulfo group a compound in which the sulfo group is substituted by an alkyl group to form a sulfonate ester may be mentioned.
- a compound having a phosphono group a compound in which the phosphono group is substituted with one or two alkyl groups to form a phosphonate monoester or a phosphonate diester is exemplified.
- alkyl portion of the group used for these prodrugs examples include the aforementioned alkyl groups, and the alkyl group may be substituted (for example, with an alkoxy group having 1 to 6 carbon atoms).
- Preferred examples of the prodrug-modified group include the following.
- Examples of a compound in which a carboxy group is an alkoxy group include a lower alkoxy group such as methoxycarbonyl and ethoxycarbonyl (for example, having 1 to 6 carbon atoms), methoxymethoxycarbonyl, ethoxymethoxycarbonyl, and the like.
- Lower for example, carbon number:! To 6
- lower for example, 1 to 6 carbon atoms
- lower for example, carbon number:! To 6
- alkoxycarbonyl such as alkoxycarbonyl, 1- (ethoxycarbonyloxy) ethyl; 3—Dihydro 3 —Oxo 1 1 _Isoben Zofuranyl) oxycarbonyl, and (5-methyl-1-oxo-1,3-dioxolen-41-yl) methoxycarbonyl.
- a sulfo group is an alkoxysulfonyl group
- examples thereof include lower (for example, 1 to 6 carbon atoms) alkoxysulfonyl and methoxysulfonyl such as methoxysulfonyl and ethoxysulfonyl.
- Ethoxymethoxis norefonyl, 2- methoxetoxysulfonyl, 2- methoxyxetoximetox Lower (e.g., C1-C4)
- Examples of compounds in which a phosphono group is an alkoxyphosphoryl group include lower (for example, carbon number) such as methoxy (hydroxy) phosphoryl, ethoxy (hydroxy) phosphoryl, dimethoxyphosphoryl, and diethoxyphosphoryl.
- the compound represented by the formula (1) or a prodrug thereof can be converted into a pharmaceutically acceptable salt, if necessary.
- salts include salts with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid; formic acid, acetic acid, fumaric acid, maleic acid, oxalic acid, citric acid, malic acid, tartaric acid, and aspartic acid.
- Salts with organic carboxylic acids such as glycerol, glutamic acid, etc .; salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-tonoleensenolephonic acid, hydroxybenzenesnolephonic acid, dihydroxybenzenesnolefonic acid; and ,
- alkali metal salts such as sodium salt and potassium salt
- alkaline earth metal salts such as calcium salt and magnesium salt
- ammonium salt triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, dicyclohexylamine salt, N, N '—Salts with dibenzylethylenediamine.
- the compound represented by the formula (1) or a prodrug thereof or a pharmaceutically acceptable salt thereof may be an anhydride, hydrate or solvate thereof.
- the compounds of the present invention can be administered orally or parenterally when using them as medicaments. That is, it can be orally administered in a commonly used dosage form, for example, in the form of powder, granules, tablets, capsules, syrups, suspensions, or the like, or, for example, in the form of a solution, emulsion, or suspension.
- the dosage form can be administered parenterally in the form of injections. It can also be administered rectally in the form of suppositories.
- the above-mentioned suitable dosage form can be produced, for example, by mixing the compound of the present invention with an acceptable usual carrier, excipient, binder, stabilizer, or diluent.
- an acceptable buffer, solubilizing agent, or isotonic agent may be added.
- the dosage and the number of administrations vary depending on, for example, the target disease, symptoms, age, body weight, and dosage form, but are usually 0.1 to 2000 mg, preferably 1 to 200 mg per day for an adult once or several times ( (For example, 2 to 4 times).
- R 31 includes the same groups as those described above for R 1 ), and one or more of R 31 may be the same or different, and any two adjacent carbon atoms of the lower alkylene group are double. A bond or a triple bond can be formed).
- these polycyclic heterocycles may include a hydrogen atom of a group represented by the formula: 1 NH— in the ring, and a substitution of the aforementioned polycyclic heterocycle. May be substituted with a group.
- Ethyl 5-pentenedoleoxy-1,4-dimethynole-1H-indole-12-force ruboxylate (4.00 g, 12.4 mmol), ammonium formate (3.90 g, 61.8 mmol), 10% palladium on Z carbon ( A mixture of 0.20 g) and ethanol (60 ml) was stirred at 60 ° C for 1.5 hours.
- the catalyst was removed by filtration, and the obtained filtrate was concentrated under reduced pressure.
- a 5% aqueous sodium chloride solution was added to the obtained residue, followed by extraction with ethyl acetate.
- the extract was washed with a 5% aqueous sodium chloride solution and dried over anhydrous magnesium sulfate.
- the solvent was distilled off under reduced pressure to obtain 2.89 g of ethyl 1,4-dimethyl-5-hydroxy 1 H-indole-2-carboxylate.
- Example 2 According to the method of Example 1, the following compounds of Example 2 and Example 3 were synthesized.
- Example 2 According to the method of Example 1, the following compounds of Example 2 and Example 3 were synthesized.
- Example 1 (d) of Example 1 was carried out using 1,4-dimethyl-17-hydroxy-1H-indole-12-forcenoreboxylate (see JP-A-8-208602, Reference Example 21) as a starting material. After performing the reaction according to the method described in 1 above, methanesulfonate is added in hydrated 2-propanol to obtain N- (aminoiminomethyl) 1,1,1-dimethinole 7-hydroxy-1 1 H-indole 1-2-kaboxamide methanesulfonate was obtained.
- Guanidine hydrochloride (6.23 g, 65.2 mmol) was added to a mixture of sodium methoxide (3.52 g, 65.2 mmol) and N, N-dimethylformamide (25 ml), and the mixture was stirred at room temperature for 1 hour.
- the precipitated solid was separated by filtration, and the filtrate obtained was (2-ethoxycarbonyl- 1-methyl-1H-indole-6-yl) 2,3,4-triacetone i3-D-gno
- a solution of lecopyranoside uronic acid (1.70 g, 3.26 mmol) in N, N-dimethylformamide (9 ml) was added, and the mixture was stirred at room temperature for 7 hours.
- Example 9 By using the same method as in Example 8, the following compounds of Example 9 and Example 10 were synthesized.
- ethyl 1-methyl-14- (trifluoromethyl) -16-vinyl-1H-indole-12-carboxylate (1.00 g, 3.36 mmol) was dissolved in tetrahydrofuran (20 ml) and dissolved in water. (10 ml) and potassium osmate (VI) dihydrate (124 mg, 0.336 ol) were added, and sodium periodate (791 mg, 3.92 ol) was dissolved in water (10 ml). The mixture was added dropwise over 20 minutes and stirred at room temperature for 5 hours.
- Example 16 The following compounds of Examples 16 to 20 were synthesized according to the method of Example 15. Example 16
- Example 22 The following compounds of Examples 22 to 26 were synthesized according to the method of Example 21.
- Example 22 The following compounds of Examples 22 to 26 were synthesized according to the method of Example 21.
- the solvent was distilled off from the reaction solution, water was added, and the mixture was washed twice with getyl ether (before the separation was difficult, a small amount of sodium chloride was added).
- the oil separated as an intermediate layer, so it was taken together as an organic layer and extracted twice more with ethyl acetate from the aqueous layer.
- Example 28 According to the method of Example 27, the following compounds of Examples 28 to 29 were synthesized.
- Example 28 According to the method of Example 27, the following compounds of Examples 28 to 29 were synthesized.
- the reaction solution was returned to room temperature, a 6N-hydrochloric acid aqueous solution was added dropwise to adjust the pH to 1, and the mixture was extracted with ethyl acetate.
- Example 31 The following compound of Example 31 was synthesized according to the method of Example 30.
- reaction solution was poured into ice water (200 ml), to which was added form (50 ml), and the precipitated solid was collected by filtration.
- the solid collected by filtration was suspended again in water, stirred at room temperature with a 6N aqueous solution of hydrochloric acid to adjust the pH to 1, filtered, washed with dimethyl ether and methanol, and dried under reduced pressure to obtain a solid solution.
- [[2 — [[[Amino (imino) methyl] amino] carbonyl] —1—Methyl-14- (triphnolelomethyl) 1-1H—Indole-61-yl] oxy] 716 mg were obtained.
- Example 33 The following compounds of Examples 33 to 36 were synthesized according to the method of Example 32.
- Example 33 The following compounds of Examples 33 to 36 were synthesized according to the method of Example 32.
- Example 40 According to the method of Example 39, the following compounds of Examples 40 to 42 were synthesized.
- Example 40 According to the method of Example 39, the following compounds of Examples 40 to 42 were synthesized.
- Example 43 According to the method of Example 43, the following compound of Example 44 was synthesized.
- getyl hydroxymethylphosphonate (3.0 g, 17.84 mmol) was dissolved in dichloromethane (30 ml) and triethylamine (4.97 ml, 35.69 mmol), and the mixture was cooled with salt ice and trifluoromethane.
- Sulfonic anhydride (3.30 ml, 19.63 ol) was added dropwise over 20 minutes, and the mixture was stirred with heating for 2 hours. Water was added to the reaction solution, the temperature was returned to room temperature, and the mixture was extracted with chloroform.
- Example 46 The following compounds of Examples 46 to 50 were synthesized according to the method of Example 45.
- Example 46 The following compounds of Examples 46 to 50 were synthesized according to the method of Example 45.
- Example 52 According to the method of Example 51, the following compounds of Examples 52 to 54 were synthesized.
- Example 52 According to the method of Example 51, the following compounds of Examples 52 to 54 were synthesized.
- a 2N aqueous solution of hydrochloric acid was added dropwise to the filtrate to adjust the pH to 5.1, and distilled water (1600 ml) was added dropwise, followed by stirring at room temperature for 1 hour.
- test was performed according to the method of Iemori et al. (J. Hypertension, 8, 153 (1990)). That is, isolated ventricular myocytes (rats) were used to evaluate the inhibitory effect of the Na + / H + exchange transport system on the index of intracellular PH change during acid loading.
- the compound of the present invention has a sodium proton (N a + / H + ) exchange transport system inhibitory action, and is a disease caused by the enhancement of the sodium Z proton (Na T ZH +) exchange transport system, such as hypertension, arrhythmia, Organ damage due to angina, heart failure, cardiac hypertrophy, diabetes, ischemia or ischemia / reperfusion (eg, myocardial ischemia / reperfusion injury, acute renal failure, surgical treatment (eg, organ transplantation and PTCA (Percutaneous Transluminal Coronary Angioplasty)), diseases caused by excessive cell proliferation (eg, fibroblast proliferation, smooth muscle cell proliferation, mesangial cell proliferation, etc.) (eg, atherosclerosis, pulmonary fibrosis, hepatic fibrosis, Renal fibrosis, glomerulosclerosis, organ hypertrophy, prostatic hypertrophy, diabetic complications, restenosis after PTCA, etc.), endothelial cell disorders, and other therapeutic and prevent
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/168,112 US6734205B2 (en) | 1999-12-16 | 2000-12-07 | Substituted guanidine derivatives |
EP00979980A EP1238971A4 (en) | 1999-12-16 | 2000-12-07 | SUBSTITUTED GUANIDINE DERIVATIVES |
AU17337/01A AU1733701A (en) | 1999-12-16 | 2000-12-07 | Substituted guanidine derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/356930 | 1999-12-16 | ||
JP35693099 | 1999-12-16 | ||
JP2000/162669 | 2000-05-31 | ||
JP2000162669 | 2000-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001044186A1 true WO2001044186A1 (fr) | 2001-06-21 |
Family
ID=26580525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/008669 WO2001044186A1 (fr) | 1999-12-16 | 2000-12-07 | Derives de guanidine substitues |
Country Status (4)
Country | Link |
---|---|
US (1) | US6734205B2 (ja) |
EP (1) | EP1238971A4 (ja) |
AU (1) | AU1733701A (ja) |
WO (1) | WO2001044186A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7875625B2 (en) | 2005-02-16 | 2011-01-25 | Toa Eiyo Ltd. | Cyclohepta[b]pyridine-3-carbonylguanidine derivative and pharmaceutical product containing same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030176357A1 (en) * | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3154520A (en) * | 1959-10-01 | 1964-10-27 | Rohm & Haas | Boron-substituted silanes and polymers therefrom |
GB1461948A (en) * | 1973-03-30 | 1977-01-19 | Fujisawa Pharmaceutical Co | 7-substituted-3-amino-alkyl-acylaminoalkyl-or hydroxyalkyl- substituted heterocyclic thiomethyl-3-cephem-4-carboxylic acid derivatives and preparation thereof |
EP0126587A1 (en) * | 1983-05-09 | 1984-11-28 | Sumitomo Pharmaceuticals Company, Limited | Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof |
EP0381033A1 (de) * | 1989-01-31 | 1990-08-08 | F. Hoffmann-La Roche Ag | Carbonsäure- und Sulfonsäureamide |
EP0622356A1 (en) * | 1993-04-28 | 1994-11-02 | Sumitomo Pharmaceuticals Company, Limited | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange |
WO1994026709A1 (en) * | 1993-05-17 | 1994-11-24 | Fujisawa Pharmaceutical Co., Ltd. | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS |
EP0708091A1 (en) * | 1994-10-18 | 1996-04-24 | Sumitomo Pharmaceuticals Company, Limited | Indoloylguanidine derivatives |
WO1997036859A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Para-substituted phenylpropanoic acid derivatives as integrin antagonists |
JPH10310582A (ja) * | 1997-03-13 | 1998-11-24 | Sankyo Co Ltd | ピペリジン環縮合カルバペネム化合物 |
WO1999055690A1 (en) * | 1998-04-24 | 1999-11-04 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
US6169107B1 (en) * | 1993-04-28 | 2001-01-02 | Sumitomo Pharmaceutical Co., Ltd. | Indoloylguanidine derivatives |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0639573A1 (de) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
US5852046A (en) * | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
NZ314105A (en) * | 1996-02-02 | 1997-12-19 | Sumitomo Pharma | Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring |
JPH10237073A (ja) | 1996-02-02 | 1998-09-08 | Sumitomo Pharmaceut Co Ltd | 新規な置換グアニジン誘導体およびその製法 |
JPH09291076A (ja) | 1996-04-24 | 1997-11-11 | Sumitomo Pharmaceut Co Ltd | 置換グアニジン誘導体およびその製法 |
TW462964B (en) | 1998-05-26 | 2001-11-11 | Sumitomo Pharma | Guanidine derivatives for the treatment and prevention of disorders caused by inhibiting hyperactivity of Na/H exchange transport system and process for producing the same |
AU3078500A (en) | 1999-01-27 | 2000-08-18 | Sumitomo Pharmaceuticals Company, Limited | Novel substituted guanidine derivatives and process for the preparation thereof |
-
2000
- 2000-12-07 US US10/168,112 patent/US6734205B2/en not_active Expired - Fee Related
- 2000-12-07 WO PCT/JP2000/008669 patent/WO2001044186A1/ja not_active Application Discontinuation
- 2000-12-07 AU AU17337/01A patent/AU1733701A/en not_active Abandoned
- 2000-12-07 EP EP00979980A patent/EP1238971A4/en not_active Withdrawn
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3154520A (en) * | 1959-10-01 | 1964-10-27 | Rohm & Haas | Boron-substituted silanes and polymers therefrom |
GB1461948A (en) * | 1973-03-30 | 1977-01-19 | Fujisawa Pharmaceutical Co | 7-substituted-3-amino-alkyl-acylaminoalkyl-or hydroxyalkyl- substituted heterocyclic thiomethyl-3-cephem-4-carboxylic acid derivatives and preparation thereof |
EP0126587A1 (en) * | 1983-05-09 | 1984-11-28 | Sumitomo Pharmaceuticals Company, Limited | Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof |
EP0381033A1 (de) * | 1989-01-31 | 1990-08-08 | F. Hoffmann-La Roche Ag | Carbonsäure- und Sulfonsäureamide |
EP0622356A1 (en) * | 1993-04-28 | 1994-11-02 | Sumitomo Pharmaceuticals Company, Limited | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange |
US6169107B1 (en) * | 1993-04-28 | 2001-01-02 | Sumitomo Pharmaceutical Co., Ltd. | Indoloylguanidine derivatives |
WO1994026709A1 (en) * | 1993-05-17 | 1994-11-24 | Fujisawa Pharmaceutical Co., Ltd. | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS |
EP0708091A1 (en) * | 1994-10-18 | 1996-04-24 | Sumitomo Pharmaceuticals Company, Limited | Indoloylguanidine derivatives |
WO1997036859A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Para-substituted phenylpropanoic acid derivatives as integrin antagonists |
JPH10310582A (ja) * | 1997-03-13 | 1998-11-24 | Sankyo Co Ltd | ピペリジン環縮合カルバペネム化合物 |
WO1999055690A1 (en) * | 1998-04-24 | 1999-11-04 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
Non-Patent Citations (10)
Title |
---|
CHEM. ANAL., vol. 31, no. 3, 1986, pages 495 - 500 * |
CHEMICAL ABSTRACTS, vol. 108, 1988, Columbus, Ohio, US; abstract no. 179135W, PIWOWARSKA, B ET AL.: "Preparation and properties of benzoylguanidine and its application in spectrophotometric determination of indium ions" XP002956902 * |
CHEMICAL ABSTRACTS, vol. 55, 1961, Columbus, Ohio, US; SKOWRONSKA-SERAFIN ET AL. column 3480; XP002956903 * |
CHEMICAL ABSTRACTS, vol. 95, Columbus, Ohio, US; abstract no. 99321, XP002944102 * |
DATABASE CAPLUS [online] XP002944101, Database accession no. 1988:179135 * |
KAMIMURA, SHOJI ET AL.: "Metabolic studies on N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride(guanfacine), a new antihypertensive agent. 2. Metabolities in blood, liver and excreta of rats after signle and repeated oral administration", OYO YAKURI, vol. 20, no. 5, 1980, pages 745 - 751, XP002937412 * |
KITANO, MASAFUMI ET AL.: "Synthesis and biological activity of N-(aminoiminomethyl)-1H-indole carboxamide derivatives as Na+/H+ exchanger inhibitors", CHEM. PHARM. BULL., vol. 47, no. 11, 1999, pages 1538 - 1548, XP002937410 * |
PROCACCINI, ROBERT L. ET AL.: "The subcellular distribution of 14C-lidamidine and its metabolites", DRUG METAB. DISPOS., vol. 9, no. 3, 1981, pages 202 - 206, XP002937413 * |
SCHMUCK, CARSTEN: "Side chain selective binding of N-acetyl-alpha-amino acid carboxylates by a 2-(guanidiniocarbonyl) pyrrole receptor in aqueous solvents", CHEM. COMMUN., no. 9, 1999, CAMBRIDGE, pages 843 - 844, XP002937411 * |
See also references of EP1238971A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7875625B2 (en) | 2005-02-16 | 2011-01-25 | Toa Eiyo Ltd. | Cyclohepta[b]pyridine-3-carbonylguanidine derivative and pharmaceutical product containing same |
Also Published As
Publication number | Publication date |
---|---|
US20030018056A1 (en) | 2003-01-23 |
US6734205B2 (en) | 2004-05-11 |
EP1238971A1 (en) | 2002-09-11 |
AU1733701A (en) | 2001-06-25 |
EP1238971A4 (en) | 2003-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI837403B (zh) | 化學化合物 | |
KR102447711B1 (ko) | 치환된 다환성 피리돈 유도체의 제조 방법 및 그의 결정 | |
CN110049977A (zh) | 作为强效和选择性rock抑制剂的内酰胺、环状脲和氨基甲酸酯及三唑酮衍生物 | |
WO1994004535A1 (en) | Trifluoromethylpyrroloindole carboxylic ester derivative and process for producing the same | |
CN109153663A (zh) | 作为rock抑制剂的三唑酮类化合物和四唑酮类化合物 | |
CN105073741A (zh) | 作为rock抑制剂的酞嗪酮及异喹啉酮 | |
RU2246493C2 (ru) | Производные индолилпиперидина в качестве антигистаминных и противоаллергических средств | |
WO2003074525A1 (fr) | Compose heterocyclique azote | |
JP7286299B2 (ja) | 1-メチル-d-トリプトファンの塩及びプロドラッグ | |
BG107460A (bg) | Производни на бензимидазола, тяхното получаване иприложението им в терапията | |
CN114981268A (zh) | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 | |
CN102482276A (zh) | 杂环化合物及其用途 | |
CN112204017A (zh) | 苯并异噁唑化合物 | |
KR20190032420A (ko) | Fgfr 억제제로서 사용되는 헤테로시클릭 화합물 | |
WO2021197452A1 (zh) | 含氮杂芳类衍生物自由碱的晶型 | |
CN112300153A (zh) | 一种杂环化合物、药物组合物和用途 | |
CN103249733A (zh) | 用于治疗或预防轻度认知障碍的稠合的三唑 | |
CN114929690A (zh) | 用于治疗心脏病的具有心肌细胞增殖活性的新型杂环衍生物 | |
WO2020200284A1 (zh) | 三环类化合物制备方法及其在医药领域的应用 | |
WO2003101983A1 (fr) | Derive tetrahydropyrane | |
WO2001044186A1 (fr) | Derives de guanidine substitues | |
TWI770858B (zh) | 嘧啶化合物及其醫藥用途 | |
JPH08208602A (ja) | インドロイルグアニジン誘導体 | |
WO2022223034A1 (zh) | Sos1降解剂及其制备方法和应用 | |
WO2014032398A1 (zh) | 哒嗪酮类化合物、其制备方法、药物组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 545274 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10168112 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000979980 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000979980 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000979980 Country of ref document: EP |